This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles
by
Junghun Park
Junghun Park 1,†,
Hyogu Han
Hyogu Han 2,3,† and
Jun Ki Ahn
Jun Ki Ahn 2,*
1
Department of Biologics, Gachon University, Incheon 21936, Republic of Korea
2
User Convenience Technology R&D Department, Korea Institute of Industrial Technology (KITECH), Ansan 15588, Republic of Korea
3
Department of Chemistry, Gangneung-Wonju National University, Gangneung,25457, Republic of Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2024, 16(10), 1288; https://doi.org/10.3390/pharmaceutics16101288 (registering DOI)
Submission received: 26 August 2024
/
Revised: 24 September 2024
/
Accepted: 26 September 2024
/
Published: 30 September 2024
Abstract
Background: The SARS-CoV-2 pandemic has highlighted niclosamide (NIC) as a promising treatment for COVID-19. However, its clinical application is limited due to its poor water solubility, resulting in low bioavailability. Methods: To address this issue, we developed a AuNP-HA-NIC system, which combines gold nanoparticles with hyaluronic acid to enhance drug delivery. Our comprehensive characterization of the system revealed that hyaluronic acid with specific molecular weights, particularly those exposed to electron-beam irradiation between 2 and 20 kGy, produced the most stable nanoparticles for efficient drug loading and delivery. Results: Additionally, the AuNP-HA-NIC system exhibits a significant sensitivity to pH changes, which is a critical feature for targeted drug release. Under acidic conditions mimicking the stomach and small intestine, minimal drug release was observed, indicating the effective prevention of premature drug release in the gastrointestinal tract. Furthermore, the integration of a targeting aptamer established specific binding abilities towards the SARS-CoV-2 spike protein, distinguishing it from other coronaviruses. Conclusions: As research progresses, and with further in vivo testing and optimization, the AuNP-HA-NIC–aptamer system holds great promise as a game-changer in the field of antiviral therapeutics, particularly in the battle against COVID-19.
Share and Cite
MDPI and ACS Style
Park, J.; Han, H.; Ahn, J.K.
Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles. Pharmaceutics 2024, 16, 1288.
https://doi.org/10.3390/pharmaceutics16101288
AMA Style
Park J, Han H, Ahn JK.
Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles. Pharmaceutics. 2024; 16(10):1288.
https://doi.org/10.3390/pharmaceutics16101288
Chicago/Turabian Style
Park, Junghun, Hyogu Han, and Jun Ki Ahn.
2024. "Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles" Pharmaceutics 16, no. 10: 1288.
https://doi.org/10.3390/pharmaceutics16101288
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.